ACOR
Acorda Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 02-14-2019 after market close | 10-31-2018 | 08-02-2018 | 05-02-2018 | 02-15-2018 | 10-31-2017 | 07-27-2017 | 04-27-2017 | |
|---|---|---|---|---|---|---|---|---|
| Actual EPS | 0.41 | 0.1 | 1.29 | -0.18 | 0.45 | -0.55 | -0.18 | -0.41 |
| Consensus EPS | -1.19 | 0.02 | 0.5 | 0.33 | 0.88 | 0.41 | 0.13 | -0.16 |
| Estimated EPS | -1.19 | 0.02 | 0.5 | 0.33 | 0.88 | 0.41 | 0.13 | -0.16 |
| Number of Estimates | 1 | 2 | 3 | 6 | 7 | 6 | 6 | 5 |
| EPS Surprise | $1.60 | $0.08 | $0.79 | -$0.51 | -$0.43 | -$0.96 | -$0.31 | -$0.25 |
Stats
Summary
Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development & commercialization of novel therapies for the treatment of neurological disorders.
Market Cap: 1.27 Billion
Primary Exchange: Nasdaq Global Select
Website: http://www.acorda.com
Shares Outstanding: 46.7 Million
Float: 45.7 Million
Dividend: 0.0 (0.0%)
Beta: 1.734379
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 5.56 Million
Ethical Flags
Longest drawdown: 1024 trading days
From: 2015-01-26 To: 2019-02-20
Lowest Point:
Acorda Therapeutics to Present at Leerink Global Healthcare Conference
via: Business Wire at 2019-02-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST. A live audio webcast of the presentation can be accessed under Investor… read more...
Acorda Therapeutics to Present at Leerink Global Healthcare Conference
via: Business Wire at 2019-02-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST. A live audio webcast of the presentation can be accessed under Investor… read more...
Acorda Therapeutics to Present at Leerink Global Healthcare Conference
via: Business Wire at 2019-02-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST. A live audio webcast of the presentation can be accessed under Investor… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-14 19:51:18:000
Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella Executive Director-Investor Relations Ron Cohen Chief Executive Officer Conference Call Participants Cory Kasimov JP M… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-14 19:51:18:000
Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella Executive Director-Investor Relations Ron Cohen Chief Executive Officer Conference Call Participants Cory Kasimov JP M… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-14 19:51:18:000
Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella Executive Director-Investor Relations Ron Cohen Chief Executive Officer Conference Call Participants Cory Kasimov JP M… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-14 19:51:18:000
Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella Executive Director-Investor Relations Ron Cohen Chief Executive Officer Conference Call Participants Cory Kasimov JP M… read more...
Acorda Therapeutics, Inc. 2019 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-02-14 17:42:07:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more … read more...
Acorda Q4 Ampyra sales down 62% on generic encroachment
via: SeekingAlpha at 2019-02-14 16:37:43:000
Acorda Therapeutics (NASDAQ: ACOR ) Q4 results ($M): Revenues: 69.2 (-63.3); Ampyra sales: 64.2 (-61.6%) due to generic competition. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Acorda Appoints Peter S. Carbone Senior Vice President, Quality
via: Business Wire at 2019-02-04 07:00:00:000
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality. Mr. Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and will be a member of the Companys Leadership Team. In his role, Mr. C… read more...
Acorda Appoints Peter S. Carbone Senior Vice President, Quality
via: Business Wire at 2019-02-04 07:00:00:000
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality. Mr. Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and will be a member of the Companys Leadership Team. In his role, Mr. C… read more...
Acorda Appoints Peter S. Carbone Senior Vice President, Quality
via: Business Wire at 2019-02-04 07:00:00:000
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality. Mr. Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and will be a member of the Companys Leadership Team. In his role, Mr. C… read more...
Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019
via: Business Wire at 2019-02-01 07:00:00:000
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results onThursday, February 14 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) o… read more...
Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019
via: Business Wire at 2019-02-01 07:00:00:000
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results onThursday, February 14 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) o… read more...
Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019
via: Business Wire at 2019-02-01 07:00:00:000
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results onThursday, February 14 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) o… read more...
New Hope For Acorda Therapeutics In 2019
via: SeekingAlpha at 2019-01-28 16:07:55:000
Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,… read more...
New Hope For Acorda Therapeutics In 2019
via: SeekingAlpha at 2019-01-28 16:07:55:000
Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,… read more...
New Hope For Acorda Therapeutics In 2019
via: SeekingAlpha at 2019-01-28 16:07:55:000
Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,… read more...
Daily Insider Ratings Round Up 1/24/19
via: SeekingAlpha at 2019-01-26 13:24:41:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/24/19
via: SeekingAlpha at 2019-01-26 13:24:41:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/22/19
via: SeekingAlpha at 2019-01-23 22:51:17:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/22/19
via: SeekingAlpha at 2019-01-23 22:51:17:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2019-01-17 18:30:00:000
SPAN-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinsons on a carbidopa/levodopa regimen INBRIJA was approved in the U.S. in Dec. 2018 and is expected to be available by… read more...
Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2019-01-17 18:30:00:000
SPAN-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinsons on a carbidopa/levodopa regimen INBRIJA was approved in the U.S. in Dec. 2018 and is expected to be available by… read more...
Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2019-01-17 18:30:00:000
SPAN-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinsons on a carbidopa/levodopa regimen INBRIJA was approved in the U.S. in Dec. 2018 and is expected to be available by… read more...
Daily Insider Ratings Round Up 1/15/19
via: SeekingAlpha at 2019-01-17 10:53:23:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/15/19
via: SeekingAlpha at 2019-01-17 10:53:23:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/15/19
via: SeekingAlpha at 2019-01-17 10:53:23:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/11/19
via: SeekingAlpha at 2019-01-15 14:21:14:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/11/19
via: SeekingAlpha at 2019-01-15 14:21:14:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/9/19
via: SeekingAlpha at 2019-01-11 15:16:45:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/9/19
via: SeekingAlpha at 2019-01-11 15:16:45:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/9/19
via: SeekingAlpha at 2019-01-11 15:16:45:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/9/19
via: SeekingAlpha at 2019-01-11 15:16:45:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round-Up 1/7/19
via: SeekingAlpha at 2019-01-09 10:25:49:000
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round-Up 1/7/19
via: SeekingAlpha at 2019-01-09 10:25:49:000
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Acorda provides 2018 highlights and 2019 guidance
via: SeekingAlpha at 2019-01-07 09:38:57:000
Acorda Therapeutics ( ACOR +0.8% ) announces its 2018 highlights and 2019 guidance: More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Acorda provides 2018 highlights and 2019 guidance
via: SeekingAlpha at 2019-01-07 09:38:57:000
Acorda Therapeutics ( ACOR +0.8% ) announces its 2018 highlights and 2019 guidance: More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference
via: Business Wire at 2019-01-07 08:00:00:000
INBRIJA (levodopa inhalation powder) approved December 21, 2018 first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinsons taking carbidopa/levodopa INBRIJA expected to be available in Q1 2019 AMPYRA&#x… read more...
Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference
via: Business Wire at 2019-01-07 08:00:00:000
INBRIJA (levodopa inhalation powder) approved December 21, 2018 first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinsons taking carbidopa/levodopa INBRIJA expected to be available in Q1 2019 AMPYRA&#x… read more...
Daily Insider Ratings Round Up 1/2/19
via: SeekingAlpha at 2019-01-03 15:40:39:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/2/19
via: SeekingAlpha at 2019-01-03 15:40:39:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 1/2/19
via: SeekingAlpha at 2019-01-03 15:40:39:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 12/28/18
via: SeekingAlpha at 2019-01-01 20:21:08:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Acorda Gets Much Needed FDA Approval To Counter Patent Setback
via: SeekingAlpha at 2018-12-31 13:17:07:000
Recently, Acorda Therapeutics ( ACOR ) announced that it had received FDA approval for its inhaled levadopa treatment for patients with Parkinson's disease ((PD)). The FDA approval of INBRIJA will definitely help add revenue for the company. It won't be blockbuster status type revenue, b… read more...
Acorda Gets Much Needed FDA Approval To Counter Patent Setback
via: SeekingAlpha at 2018-12-31 13:17:07:000
Recently, Acorda Therapeutics ( ACOR ) announced that it had received FDA approval for its inhaled levadopa treatment for patients with Parkinson's disease ((PD)). The FDA approval of INBRIJA will definitely help add revenue for the company. It won't be blockbuster status type revenue, b… read more...
Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts
via: SeekingAlpha at 2018-12-28 18:37:48:000
It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...
Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts
via: SeekingAlpha at 2018-12-28 18:37:48:000
It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...
Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts
via: SeekingAlpha at 2018-12-28 18:37:48:000
It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...
Adamas Knife Continues To Fall As Value Continues To Rise
via: SeekingAlpha at 2018-12-26 14:59:04:000
Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS… read more...
Adamas Knife Continues To Fall As Value Continues To Rise
via: SeekingAlpha at 2018-12-26 14:59:04:000
Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS… read more...
Adamas Knife Continues To Fall As Value Continues To Rise
via: SeekingAlpha at 2018-12-26 14:59:04:000
Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS… read more...
Thin ranks in premarket gainers
via: SeekingAlpha at 2018-12-24 09:13:48:000
MINDBODY (NASDAQ: MB ) +68% on being acquired byVista Equity Partners for $1.9B. More news on: Mindbody, Acorda Therapeutics, Inc., Stocks on the move, , Read more … read more...
Thin ranks in premarket gainers
via: SeekingAlpha at 2018-12-24 09:13:48:000
MINDBODY (NASDAQ: MB ) +68% on being acquired byVista Equity Partners for $1.9B. More news on: Mindbody, Acorda Therapeutics, Inc., Stocks on the move, , Read more … read more...
Acorda Therapeutics announces FDA approval of INBRIJA
via: SeekingAlpha at 2018-12-24 06:41:08:000
The FDA approves Acorda Therapeutics' (NASDAQ: ACOR ) INBRIJA for intermittent treatment of OFF episodes in people with Parkinsons disease treated with carbidopa/levodopa. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Read more … read more...
Acorda Therapeutics announces FDA approval of INBRIJA
via: SeekingAlpha at 2018-12-24 06:41:08:000
The FDA approves Acorda Therapeutics' (NASDAQ: ACOR ) INBRIJA for intermittent treatment of OFF episodes in people with Parkinsons disease treated with carbidopa/levodopa. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Read more … read more...
Acorda Therapeutics Announces FDA Approval of INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-12-21 21:53:00:000
First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinsons Taking Carbidopa/Levodopa Expected to be Available by Prescription in First Quarter 2019 Based on Innovative ARCUS Technology Platform for Inhaled Drug … read more...
Acorda Therapeutics Announces FDA Approval of INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-12-21 21:53:00:000
First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinsons Taking Carbidopa/Levodopa Expected to be Available by Prescription in First Quarter 2019 Based on Innovative ARCUS Technology Platform for Inhaled Drug … read more...
Daily Insider Ratings Round Up 12/17/18
via: SeekingAlpha at 2018-12-20 16:26:25:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 12/17/18
via: SeekingAlpha at 2018-12-20 16:26:25:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Acorda to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2018-12-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 at 8:00am PST / 5:00am EST. A live audio webcast of the presentation can be acc… read more...
Daily Insider Ratings Round Up 12/13/18
via: SeekingAlpha at 2018-12-15 13:24:07:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 12/13/18
via: SeekingAlpha at 2018-12-15 13:24:07:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 12/13/18
via: SeekingAlpha at 2018-12-15 13:24:07:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 12/13/18
via: SeekingAlpha at 2018-12-15 13:24:07:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
SFIX and FRAN among premarket losers
via: SeekingAlpha at 2018-12-11 09:09:11:000
Stitch Fix (NASDAQ: SFIX ) -19% on Q1 earnings . More news on: Stitch Fix, Inc., Acorda Therapeutics, Inc., Francesca's Holdings Corp., Stocks on the move, , Read more … read more...
SFIX and FRAN among premarket losers
via: SeekingAlpha at 2018-12-11 09:09:11:000
Stitch Fix (NASDAQ: SFIX ) -19% on Q1 earnings . More news on: Stitch Fix, Inc., Acorda Therapeutics, Inc., Francesca's Holdings Corp., Stocks on the move, , Read more … read more...
Acorda down 12% on Goldman cut in premarket analyst action
via: SeekingAlpha at 2018-12-11 08:58:39:000
Novavax (NASDAQ: NVAX ) initiated with Outperform rating and $4 (87% upside) price target at Oppenheimer. Shares up 3% premarket. More news on: Novavax, Inc., Synthetic Biologics, Inc., BioTime, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Acorda down 12% on Goldman cut in premarket analyst action
via: SeekingAlpha at 2018-12-11 08:58:39:000
Novavax (NASDAQ: NVAX ) initiated with Outperform rating and $4 (87% upside) price target at Oppenheimer. Shares up 3% premarket. More news on: Novavax, Inc., Synthetic Biologics, Inc., BioTime, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Daily Insider Ratings Round Up 12/3/18
via: SeekingAlpha at 2018-12-05 10:00:25:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round Up 12/3/18
via: SeekingAlpha at 2018-12-05 10:00:25:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round Up 12/3/18
via: SeekingAlpha at 2018-12-05 10:00:25:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Acorda Launches Art Initiative to Foster Better Conversations About Parkinson's Symptoms
via: Business Wire at 2018-12-05 07:00:00:000
Framing OFF Through Art Uses the Power of Art to Illustrate the Impact of OFF Periods Acorda Therapeutics, Inc. (Nasdaq:ACOR) today launched Framing OFF Through Art , a new initiative that uses the power of art to allow people with Parkinsons to help recognize… read more...
Acorda Launches Art Initiative to Foster Better Conversations About Parkinson's Symptoms
via: Business Wire at 2018-12-05 07:00:00:000
Framing OFF Through Art Uses the Power of Art to Illustrate the Impact of OFF Periods Acorda Therapeutics, Inc. (Nasdaq:ACOR) today launched Framing OFF Through Art , a new initiative that uses the power of art to allow people with Parkinsons to help recognize… read more...
Acorda Launches Art Initiative to Foster Better Conversations About Parkinson's Symptoms
via: Business Wire at 2018-12-05 07:00:00:000
Framing OFF Through Art Uses the Power of Art to Illustrate the Impact of OFF Periods Acorda Therapeutics, Inc. (Nasdaq:ACOR) today launched Framing OFF Through Art , a new initiative that uses the power of art to allow people with Parkinsons to help recognize… read more...
ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q3 2018
via: SeekingAlpha at 2018-11-22 20:48:00:000
Read more … read more...
ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q3 2018
via: SeekingAlpha at 2018-11-22 20:48:00:000
Read more … read more...
ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q3 2018
via: SeekingAlpha at 2018-11-22 20:48:00:000
Read more … read more...
ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q3 2018
via: SeekingAlpha at 2018-11-22 20:48:00:000
Read more … read more...
ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q3 2018
via: SeekingAlpha at 2018-11-22 20:48:00:000
Read more … read more...
Acorda to Present at Stifel 2018 Healthcare Conference
via: Business Wire at 2018-11-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13 at 2:00pm EST. A live audio webcast of the presentation can be accessed under Investor Events in t… read more...
Acorda to Present at Stifel 2018 Healthcare Conference
via: Business Wire at 2018-11-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13 at 2:00pm EST. A live audio webcast of the presentation can be accessed under Investor Events in t… read more...
Acorda to Present at Stifel 2018 Healthcare Conference
via: Business Wire at 2018-11-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13 at 2:00pm EST. A live audio webcast of the presentation can be accessed under Investor Events in t… read more...
Centrexion Therapeutics Seeks $75 Million In Proposed IPO
via: SeekingAlpha at 2018-11-05 13:56:42:000
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...
Centrexion Therapeutics Seeks $75 Million In Proposed IPO
via: SeekingAlpha at 2018-11-05 13:56:42:000
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...
Centrexion Therapeutics Seeks $75 Million In Proposed IPO
via: SeekingAlpha at 2018-11-05 13:56:42:000
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-10-31 14:36:04:000
Acorda Therapeutics, Inc. (ACOR) Q3 2018 Earnings Conference Call October 31, 2018 8:30 A.M. ET Executives Felicia Vonella - Executive Director-Investor Relations Ron Cohen - Chief Executive Officer Analysts Carmen Augustine - JPMorgan Kelechi Chikere - Jefferies Phil Nad… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-10-31 14:36:04:000
Acorda Therapeutics, Inc. (ACOR) Q3 2018 Earnings Conference Call October 31, 2018 8:30 A.M. ET Executives Felicia Vonella - Executive Director-Investor Relations Ron Cohen - Chief Executive Officer Analysts Carmen Augustine - JPMorgan Kelechi Chikere - Jefferies Phil Nad… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-10-31 14:36:04:000
Acorda Therapeutics, Inc. (ACOR) Q3 2018 Earnings Conference Call October 31, 2018 8:30 A.M. ET Executives Felicia Vonella - Executive Director-Investor Relations Ron Cohen - Chief Executive Officer Analysts Carmen Augustine - JPMorgan Kelechi Chikere - Jefferies Phil Nad… read more...
Acorda Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-10-31 09:28:27:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Acorda Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-10-31 09:28:27:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Acorda Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-10-31 09:28:27:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Acorda Therapeutics beats by $0.31, beats on revenue
via: SeekingAlpha at 2018-10-31 06:01:21:000
Acorda Therapeutics (NASDAQ: ACOR ): Q3 Non-GAAP EPS of $0.17 beats by $0.31 ; GAAP EPS of -$0.29 beats by $0.01 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics beats by $0.31, beats on revenue
via: SeekingAlpha at 2018-10-31 06:01:21:000
Acorda Therapeutics (NASDAQ: ACOR ): Q3 Non-GAAP EPS of $0.17 beats by $0.31 ; GAAP EPS of -$0.29 beats by $0.01 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics beats by $0.31, beats on revenue
via: SeekingAlpha at 2018-10-31 06:01:21:000
Acorda Therapeutics (NASDAQ: ACOR ): Q3 Non-GAAP EPS of $0.17 beats by $0.31 ; GAAP EPS of -$0.29 beats by $0.01 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Provides Financial and Pipeline Update for Third Quarter 2018
via: Business Wire at 2018-10-31 06:00:00:000
AMPYRA (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million Cash balance for year-end 2018 revised from more than $300 million to more than $400 million INBRIJA (levodopa inhalation… read more...
Acorda Provides Financial and Pipeline Update for Third Quarter 2018
via: Business Wire at 2018-10-31 06:00:00:000
AMPYRA (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million Cash balance for year-end 2018 revised from more than $300 million to more than $400 million INBRIJA (levodopa inhalation… read more...
Acorda Provides Financial and Pipeline Update for Third Quarter 2018
via: Business Wire at 2018-10-31 06:00:00:000
AMPYRA (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million Cash balance for year-end 2018 revised from more than $300 million to more than $400 million INBRIJA (levodopa inhalation… read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-10-30 17:30:38:000
ACOR , ADP , AEE , AIT , ANTM , APO , APTV , ARCC , AUO , BAX , BCOR , BDC , BG , CAMT , CBZ , CDW , CG , CIM , CLH , CLX , CRTO , CVE , DBD , DIN , EGL , EL , EPD , ETR , GM , GNC , GRMN , HCP , HES , HFC , HSC , IART , ICE , ICPT , IGT , K , LFUS ,… read more...
Centrexion Therapeutics Begins U.S. IPO Effort
via: SeekingAlpha at 2018-10-25 16:11:14:000
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...
Centrexion Therapeutics Begins U.S. IPO Effort
via: SeekingAlpha at 2018-10-25 16:11:14:000
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...
Centrexion Therapeutics Begins U.S. IPO Effort
via: SeekingAlpha at 2018-10-25 16:11:14:000
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...
Acorda up 8% premarket on closure of FDA inspections
via: SeekingAlpha at 2018-10-18 09:08:07:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 8% premarket on light volume on the heels of its disclosure that the FDA's pre-approval inspections of its Chelsea, MA manufacturing facility and the Inbrija inhaler device maker's facility have been completed with no further action req… read more...
Acorda up 8% premarket on closure of FDA inspections
via: SeekingAlpha at 2018-10-18 09:08:07:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 8% premarket on light volume on the heels of its disclosure that the FDA's pre-approval inspections of its Chelsea, MA manufacturing facility and the Inbrija inhaler device maker's facility have been completed with no further action req… read more...
Acorda up 8% premarket on closure of FDA inspections
via: SeekingAlpha at 2018-10-18 09:08:07:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 8% premarket on light volume on the heels of its disclosure that the FDA's pre-approval inspections of its Chelsea, MA manufacturing facility and the Inbrija inhaler device maker's facility have been completed with no further action req… read more...
Acorda Third Quarter 2018 Update: Webcast/Conference Call Scheduled for October 31, 2018
via: Business Wire at 2018-10-17 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2018 update and financial results onWednesday, October 31 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (int… read more...
Daily Insider Ratings Round-Up 10/12/18
via: SeekingAlpha at 2018-10-15 13:39:25:000
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round-Up 10/12/18
via: SeekingAlpha at 2018-10-15 13:39:25:000
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 10/4/18
via: SeekingAlpha at 2018-10-06 12:30:08:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 10/4/18
via: SeekingAlpha at 2018-10-06 12:30:08:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 10/4/18
via: SeekingAlpha at 2018-10-06 12:30:08:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 10/4/18
via: SeekingAlpha at 2018-10-06 12:30:08:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Acorda to Present Data for INBRIJA(TM) (levodopa inhalation powder) at International Congress of Parkinson's Disease and Movement Disorders
via: Business Wire at 2018-10-02 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinsons Disease and Movement Disorders taking place October 5-9, 2018 in Hong Kong.INBR… read more...
Acorda to Present Data for INBRIJA(TM) (levodopa inhalation powder) at International Congress of Parkinson's Disease and Movement Disorders
via: Business Wire at 2018-10-02 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinsons Disease and Movement Disorders taking place October 5-9, 2018 in Hong Kong.INBR… read more...
Acorda to Present Data for INBRIJA(TM) (levodopa inhalation powder) at International Congress of Parkinson's Disease and Movement Disorders
via: Business Wire at 2018-10-02 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinsons Disease and Movement Disorders taking place October 5-9, 2018 in Hong Kong.INBR… read more...
Acorda Has Suffered Two Setbacks, Both Of Which Can Be Dealt With
via: SeekingAlpha at 2018-09-18 09:11:08:000
The previous week was a rough one for Acorda Therapeutics ( ACOR ) but I believe that it will recover. The first issue was that the FDA pushed back the PDUFA date for its inhaled therapy for Parkinson's disease by many months. The second problem lies with not being able to uphold patents wit… read more...
Acorda Has Suffered Two Setbacks, Both Of Which Can Be Dealt With
via: SeekingAlpha at 2018-09-18 09:11:08:000
The previous week was a rough one for Acorda Therapeutics ( ACOR ) but I believe that it will recover. The first issue was that the FDA pushed back the PDUFA date for its inhaled therapy for Parkinson's disease by many months. The second problem lies with not being able to uphold patents wit… read more...
Acorda Has Suffered Two Setbacks, Both Of Which Can Be Dealt With
via: SeekingAlpha at 2018-09-18 09:11:08:000
The previous week was a rough one for Acorda Therapeutics ( ACOR ) but I believe that it will recover. The first issue was that the FDA pushed back the PDUFA date for its inhaled therapy for Parkinson's disease by many months. The second problem lies with not being able to uphold patents wit… read more...
Your Daily Pharma Scoop: XBiotech Reports Positive Data, AstraZeneca's New Approval, Novartis' Positive MS Trial
via: SeekingAlpha at 2018-09-17 08:35:30:000
Stocks in News: [[XBIT]], [[AZN]] XBiotech's bermekimab shows positive effect in dermatitis pilot study XBiotech reported preliminary positive data from an open-label, dose escalation study of Phase 2 trial assessing its bermekimab candidate in moderate to severe atopic dermatitis ((… read more...
Acorda Announces FDA Extends INBRIJA NDA Review Period
via: Business Wire at 2018-09-13 07:00:00:000
New PDUFA Date of January 5, 2019 Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of INBRIJA (levodopa in… read more...
Acorda Announces FDA Extends INBRIJA NDA Review Period
via: Business Wire at 2018-09-13 07:00:00:000
New PDUFA Date of January 5, 2019 Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of INBRIJA (levodopa in… read more...
Acorda Announces FDA Extends INBRIJA NDA Review Period
via: Business Wire at 2018-09-13 07:00:00:000
New PDUFA Date of January 5, 2019 Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of INBRIJA (levodopa in… read more...
Midday Gainers / Losers (09/10/2018)
via: SeekingAlpha at 2018-09-10 12:56:51:000
Gainers: FRED +66% . RMNI +25% . DCTH +19% . TLRY +13% . PRQR +13% . NMIH +11% . OBLN +11% . SIEB +11% . FTEK +10% . NEWA +10% . More news on: Fred's, Inc., Rimini Street, Delcath Systems, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (09/10/2018)
via: SeekingAlpha at 2018-09-10 12:56:51:000
Gainers: FRED +66% . RMNI +25% . DCTH +19% . TLRY +13% . PRQR +13% . NMIH +11% . OBLN +11% . SIEB +11% . FTEK +10% . NEWA +10% . More news on: Fred's, Inc., Rimini Street, Delcath Systems, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (09/10/2018)
via: SeekingAlpha at 2018-09-10 12:56:51:000
Gainers: FRED +66% . RMNI +25% . DCTH +19% . TLRY +13% . PRQR +13% . NMIH +11% . OBLN +11% . SIEB +11% . FTEK +10% . NEWA +10% . More news on: Fred's, Inc., Rimini Street, Delcath Systems, Inc., Stocks on the move, , Read more … read more...
U.S. Court of Appeals for the Federal Circuit Upholds District Court's Decision to Invalidate AMPYRA® (dalfampridine) Patents
via: Business Wire at 2018-09-10 11:47:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delawares decision to invalidate four AMPYRA patents. This decision affirms the Dist… read more...
U.S. Court of Appeals for the Federal Circuit Upholds District Court's Decision to Invalidate AMPYRA® (dalfampridine) Patents
via: Business Wire at 2018-09-10 11:47:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delawares decision to invalidate four AMPYRA patents. This decision affirms the Dist… read more...
U.S. Court of Appeals for the Federal Circuit Upholds District Court's Decision to Invalidate AMPYRA® (dalfampridine) Patents
via: Business Wire at 2018-09-10 11:47:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delawares decision to invalidate four AMPYRA patents. This decision affirms the Dist… read more...
Acorda announces Management transitions
via: SeekingAlpha at 2018-08-14 07:29:53:000
Rick Batycky, Ph.D., Chief Technology Officer of Acorda Therapeutics (NASDAQ: ACOR ) will be stepping down , effectiveAugust 20. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Read more … read more...
Acorda announces Management transitions
via: SeekingAlpha at 2018-08-14 07:29:53:000
Rick Batycky, Ph.D., Chief Technology Officer of Acorda Therapeutics (NASDAQ: ACOR ) will be stepping down , effectiveAugust 20. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Read more … read more...
Acorda announces Management transitions
via: SeekingAlpha at 2018-08-14 07:29:53:000
Rick Batycky, Ph.D., Chief Technology Officer of Acorda Therapeutics (NASDAQ: ACOR ) will be stepping down , effectiveAugust 20. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Read more … read more...
Acorda Announces Management Transitions
via: Business Wire at 2018-08-14 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acordas Chief of Business Operat… read more...
Acorda Announces Management Transitions
via: Business Wire at 2018-08-14 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acordas Chief of Business Operat… read more...
Acorda Announces Management Transitions
via: Business Wire at 2018-08-14 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acordas Chief of Business Operat… read more...
Stocks To Watch: Any Privacy For Tesla?
via: SeekingAlpha at 2018-08-11 09:07:58:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...
Stocks To Watch: Any Privacy For Tesla?
via: SeekingAlpha at 2018-08-11 09:07:58:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...
Stocks To Watch: Any Privacy For Tesla?
via: SeekingAlpha at 2018-08-11 09:07:58:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Your Daily Pharma Scoop: Insmed's AdCom, Opko Progresses, Roche PRIMEd
via: SeekingAlpha at 2018-08-06 01:39:48:000
Stocks in News: INSM, OPK Insmed up 7% premarket ahead of Ad Com review of inhalable amikacin for NTM lung disease Discussion : Insmed ( INSM ) released briefing documents before upcoming Ad Com on Aug 7. The Ad Com will review the companys marketing application for amikacin l… read more...
Looking For Action? S&P 1500 Most Volatile Stocks
via: SeekingAlpha at 2018-08-03 17:12:41:000
For traders with a short-term time horizon looking for big moves, we have updated our list of the S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread between the intraday high and low over the last 50 days). The stocks are g… read more...
Looking For Action? S&P 1500 Most Volatile Stocks
via: SeekingAlpha at 2018-08-03 17:12:41:000
For traders with a short-term time horizon looking for big moves, we have updated our list of the S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread between the intraday high and low over the last 50 days). The stocks are g… read more...
Looking For Action? S&P 1500 Most Volatile Stocks
via: SeekingAlpha at 2018-08-03 17:12:41:000
For traders with a short-term time horizon looking for big moves, we have updated our list of the S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread between the intraday high and low over the last 50 days). The stocks are g… read more...
Acorda working through Ampyra patent infringement cases
via: SeekingAlpha at 2018-08-03 07:42:01:000
Acorda Therapeutics (NASDAQ: ACOR ) has entered into a conditioned settlement agreement with Mylan (NASDAQ: MYL ) that will allow it to market a generic version of Ampyra (dalfampridine) sometime in 2025 or earlier under certain circumstances. More news on: Acorda Therapeutics, Inc., Myl… read more...
Acorda working through Ampyra patent infringement cases
via: SeekingAlpha at 2018-08-03 07:42:01:000
Acorda Therapeutics (NASDAQ: ACOR ) has entered into a conditioned settlement agreement with Mylan (NASDAQ: MYL ) that will allow it to market a generic version of Ampyra (dalfampridine) sometime in 2025 or earlier under certain circumstances. More news on: Acorda Therapeutics, Inc., Myl… read more...
Acorda working through Ampyra patent infringement cases
via: SeekingAlpha at 2018-08-03 07:42:01:000
Acorda Therapeutics (NASDAQ: ACOR ) has entered into a conditioned settlement agreement with Mylan (NASDAQ: MYL ) that will allow it to market a generic version of Ampyra (dalfampridine) sometime in 2025 or earlier under certain circumstances. More news on: Acorda Therapeutics, Inc., Myl… read more...
Acorda sees Ampyra sales as high as $350M this year
via: SeekingAlpha at 2018-08-03 07:29:58:000
Acorda Therapeutics (NASDAQ: ACOR ) Q2 results ($M): Revenues: 153.3 (+10.0%); Ampyra sales: 150.3 (+42.1%). More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Acorda sees Ampyra sales as high as $350M this year
via: SeekingAlpha at 2018-08-03 07:29:58:000
Acorda Therapeutics (NASDAQ: ACOR ) Q2 results ($M): Revenues: 153.3 (+10.0%); Ampyra sales: 150.3 (+42.1%). More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Acorda sees Ampyra sales as high as $350M this year
via: SeekingAlpha at 2018-08-03 07:29:58:000
Acorda Therapeutics (NASDAQ: ACOR ) Q2 results ($M): Revenues: 153.3 (+10.0%); Ampyra sales: 150.3 (+42.1%). More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 14:35:57:000
Acorda Therapeutics, Inc. (ACOR) Q2 2018 Earnings Conference Call August 2, 2018 8:30 AM ET Executives Felicia Vonella Executive Director-Investor Relations Ron Cohen Chief Executive Officer David Lawrence Chief, Business Operations and Principal Accoun… read more...
Acorda Therapeutics, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-02 14:14:33:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Acorda Therapeutics beats by $0.68, beats on revenue
via: SeekingAlpha at 2018-08-02 06:07:14:000
Acorda Therapeutics (NASDAQ: ACOR ): Q2 EPS of $1.40 beats by $0.68 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Provides Financial and Pipeline Update for Second Quarter 2018
via: Business Wire at 2018-08-02 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA under FDA review; PDUFA date October 5, 2018 AMPYRA (dalfampridine) 2Q 2018 net sales of $150.3 million; reiterating 2018 guidance of $330-$350 million Awaiting AMPYRA patent decision from U.S. Court of Appeals Acorda Th… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-08-01 17:30:46:000
AAON , AAWW , ABC , ACIW , ACOR , AET , AGIO , ALE , ALNY , AMAG , AMCX , APO , APRN , ARES , AROC , ARW , AVP , BCE , BDX , BLL , BSIG , CBM , CBRE , CBZ , CCOI , CDW , CEIX , CHD , CI , CJ , CLX , CNQ , CNSL , CNX , CNXM , COT , CRS , CTSH , DNOW , … read more...
Acorda Second Quarter Update: Webcast/Conference Call Scheduled for August 2, 2018
via: Business Wire at 2018-07-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results onThursday, August 2 at 8:30 a.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (inter… read more...
Acorda Second Quarter Update: Webcast/Conference Call Scheduled for August 2, 2018
via: Business Wire at 2018-07-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results onThursday, August 2 at 8:30 a.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (inter… read more...
Acorda Second Quarter Update: Webcast/Conference Call Scheduled for August 2, 2018
via: Business Wire at 2018-07-19 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results onThursday, August 2 at 8:30 a.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (inter… read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Drug prices still marching upward - Bloomberg
via: SeekingAlpha at 2018-07-12 12:20:07:000
Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...
Drug prices still marching upward - Bloomberg
via: SeekingAlpha at 2018-07-12 12:20:07:000
Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...
Drug prices still marching upward - Bloomberg
via: SeekingAlpha at 2018-07-12 12:20:07:000
Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...
Acorda to Present Data for INBRIJA(TM) (levodopa inhalation powder) at 2nd Pan American Parkinson's Disease and Movement Disorders Congress
via: Business Wire at 2018-06-18 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present four encore INBRIJA posters at the upcoming 2 nd Pan American Parkinsons Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida. INBRIJA is an investigational inhaled levodopa treatment for sympto… read more...
Acorda to Present Data for INBRIJA(TM) (levodopa inhalation powder) at 2nd Pan American Parkinson's Disease and Movement Disorders Congress
via: Business Wire at 2018-06-18 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present four encore INBRIJA posters at the upcoming 2 nd Pan American Parkinsons Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida. INBRIJA is an investigational inhaled levodopa treatment for sympto… read more...
Acorda to Present Data for INBRIJA(TM) (levodopa inhalation powder) at 2nd Pan American Parkinson's Disease and Movement Disorders Congress
via: Business Wire at 2018-06-18 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present four encore INBRIJA posters at the upcoming 2 nd Pan American Parkinsons Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida. INBRIJA is an investigational inhaled levodopa treatment for sympto… read more...
Midday Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 12:40:15:000
Gainers: TPIV +71% . EDAP +63% . SVRA +30% . ACOR +19% . SFIX +15% . TTOO +13% . NFEC +13% . AZRX +13% . VSI +12% . ZYME +13% . More news on: TapImmune, Inc., EDAP TMS S.A., Savara Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 12:40:15:000
Gainers: TPIV +71% . EDAP +63% . SVRA +30% . ACOR +19% . SFIX +15% . TTOO +13% . NFEC +13% . AZRX +13% . VSI +12% . ZYME +13% . More news on: TapImmune, Inc., EDAP TMS S.A., Savara Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 12:40:15:000
Gainers: TPIV +71% . EDAP +63% . SVRA +30% . ACOR +19% . SFIX +15% . TTOO +13% . NFEC +13% . AZRX +13% . VSI +12% . ZYME +13% . More news on: TapImmune, Inc., EDAP TMS S.A., Savara Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 12:40:15:000
Gainers: TPIV +71% . EDAP +63% . SVRA +30% . ACOR +19% . SFIX +15% . TTOO +13% . NFEC +13% . AZRX +13% . VSI +12% . ZYME +13% . More news on: TapImmune, Inc., EDAP TMS S.A., Savara Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/08/2018)
via: SeekingAlpha at 2018-06-08 12:40:15:000
Gainers: TPIV +71% . EDAP +63% . SVRA +30% . ACOR +19% . SFIX +15% . TTOO +13% . NFEC +13% . AZRX +13% . VSI +12% . ZYME +13% . More news on: TapImmune, Inc., EDAP TMS S.A., Savara Inc., Stocks on the move, , Read more … read more...
Acorda adds to rally, up 24%
via: SeekingAlpha at 2018-06-08 10:39:41:000
Thinly traded Acorda Therapeutics ( ACOR +23.8% ) is up again on almost a 6x surge in volume. Shares have rallied 50% since May 23. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Acorda adds to rally, up 24%
via: SeekingAlpha at 2018-06-08 10:39:41:000
Thinly traded Acorda Therapeutics ( ACOR +23.8% ) is up again on almost a 6x surge in volume. Shares have rallied 50% since May 23. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Acorda adds to rally, up 24%
via: SeekingAlpha at 2018-06-08 10:39:41:000
Thinly traded Acorda Therapeutics ( ACOR +23.8% ) is up again on almost a 6x surge in volume. Shares have rallied 50% since May 23. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Acorda adds to rally, up 24%
via: SeekingAlpha at 2018-06-08 10:39:41:000
Thinly traded Acorda Therapeutics ( ACOR +23.8% ) is up again on almost a 6x surge in volume. Shares have rallied 50% since May 23. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Acorda adds to rally, up 24%
via: SeekingAlpha at 2018-06-08 10:39:41:000
Thinly traded Acorda Therapeutics ( ACOR +23.8% ) is up again on almost a 6x surge in volume. Shares have rallied 50% since May 23. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
EMA accepts Acorda's marketing application for Parkinson's med Inbrija
via: SeekingAlpha at 2018-05-29 08:06:14:000
The European Medicines Agency (EMA) has accepted for review Acorda Therapeutics' (NASDAQ: ACOR ) marketing application seeking approval for INBRIJA (levodopa inhalation powder) for the treatment of OFF periods in Parkinson's disease patients taking a carbidopa/levodopa regimen. More news… read more...
EMA accepts Acorda's marketing application for Parkinson's med Inbrija
via: SeekingAlpha at 2018-05-29 08:06:14:000
The European Medicines Agency (EMA) has accepted for review Acorda Therapeutics' (NASDAQ: ACOR ) marketing application seeking approval for INBRIJA (levodopa inhalation powder) for the treatment of OFF periods in Parkinson's disease patients taking a carbidopa/levodopa regimen. More news… read more...
EMA accepts Acorda's marketing application for Parkinson's med Inbrija
via: SeekingAlpha at 2018-05-29 08:06:14:000
The European Medicines Agency (EMA) has accepted for review Acorda Therapeutics' (NASDAQ: ACOR ) marketing application seeking approval for INBRIJA (levodopa inhalation powder) for the treatment of OFF periods in Parkinson's disease patients taking a carbidopa/levodopa regimen. More news… read more...
Acorda Announces EMA Validation of the MAA Submission for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-05-29 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the European Medicines Agency (EMA) has completed formal validation of Acordas Marketing Authorization Application (MAA) for INBRIJA. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in … read more...
Acorda Announces EMA Validation of the MAA Submission for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-05-29 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the European Medicines Agency (EMA) has completed formal validation of Acordas Marketing Authorization Application (MAA) for INBRIJA. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in … read more...
Acorda Announces EMA Validation of the MAA Submission for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-05-29 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the European Medicines Agency (EMA) has completed formal validation of Acordas Marketing Authorization Application (MAA) for INBRIJA. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in … read more...
Acorda Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-05-03 13:16:41:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q1 earnings Read more … read more...
Acorda Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-05-03 13:16:41:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q1 earnings Read more … read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-02 13:31:03:000
Acorda Therapeutics, Inc. (ACOR) Q1 2018 Earnings Conference Call May 02, 2018, 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Phil Nadeau - Cowen an… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-02 13:31:03:000
Acorda Therapeutics, Inc. (ACOR) Q1 2018 Earnings Conference Call May 02, 2018, 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Phil Nadeau - Cowen an… read more...
Acorda Therapeutics misses by $0.33, misses on revenue
via: SeekingAlpha at 2018-05-02 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q1 EPS of $0.14 misses by $0.33 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.33, misses on revenue
via: SeekingAlpha at 2018-05-02 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q1 EPS of $0.14 misses by $0.33 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Provides Financial and Pipeline Update for First Quarter 2018
via: Business Wire at 2018-05-02 06:00:00:000
FDA accepted INBRIJA (levodopa inhalation powder) NDA; PDUFA date October 5, 2018 Marketing Authorization Application (MAA) for INBRIJA submitted to the European Medicines Agency (EMA) on March 26, 2018 AMPYRA (dalfampridine) 1Q 2018 net sales of $103 million; reite… read more...
Acorda Provides Financial and Pipeline Update for First Quarter 2018
via: Business Wire at 2018-05-02 06:00:00:000
FDA accepted INBRIJA (levodopa inhalation powder) NDA; PDUFA date October 5, 2018 Marketing Authorization Application (MAA) for INBRIJA submitted to the European Medicines Agency (EMA) on March 26, 2018 AMPYRA (dalfampridine) 1Q 2018 net sales of $103 million; reite… read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-05-01 17:30:44:000
ABC , ACOR , ADP , ALE , AME , AMRN , APTV , ARCC , ASC , AVA , BDC , BG , BPMC , CAMT , CBRE , CDW , CHK , CLH , CLX , CPLA , CRTO , CVS , DBD , DIN , DNOW , EGL , EL , ENBL , ENR , EXC , FLOW , FUN , GIB , GLDD , GNRC , GRMN , HFC , HRS , HSC , HUM … read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-05-01 17:30:44:000
ABC , ACOR , ADP , ALE , AME , AMRN , APTV , ARCC , ASC , AVA , BDC , BG , BPMC , CAMT , CBRE , CDW , CHK , CLH , CLX , CPLA , CRTO , CVS , DBD , DIN , DNOW , EGL , EL , ENBL , ENR , EXC , FLOW , FUN , GIB , GLDD , GNRC , GRMN , HFC , HRS , HSC , HUM … read more...
Institutional Top Ideas Series: Scopia Capital
via: SeekingAlpha at 2018-04-19 12:12:03:000
In the last entry of this series, we took a look at top ideas from DAFNA Capital Management (whose performance practically tripled that of the IBB during the time frame we looked at). Going forward, I hope to continue to delve into the portfolios of successful hedge funds predominantly i… read more...
Institutional Top Ideas Series: Scopia Capital
via: SeekingAlpha at 2018-04-19 12:12:03:000
In the last entry of this series, we took a look at top ideas from DAFNA Capital Management (whose performance practically tripled that of the IBB during the time frame we looked at). Going forward, I hope to continue to delve into the portfolios of successful hedge funds predominantly i… read more...
Acorda to Present New Data For INBRIJA(TM) (levodopa inhalation powder) at 70th American Academy of Neurology Annual Meeting
via: Business Wire at 2018-04-16 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 2127, 2018. INBRIJA is an investigational inhaled levodopa treatment for … read more...
Acorda to Present New Data For INBRIJA(TM) (levodopa inhalation powder) at 70th American Academy of Neurology Annual Meeting
via: Business Wire at 2018-04-16 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 2127, 2018. INBRIJA is an investigational inhaled levodopa treatment for … read more...
Acorda First Quarter Update: Webcast/Conference Call Scheduled for May 2, 2018
via: Business Wire at 2018-04-11 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2018 financial results onWednesday, May 2 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (international) and … read more...
Acorda First Quarter Update: Webcast/Conference Call Scheduled for May 2, 2018
via: Business Wire at 2018-04-11 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2018 financial results onWednesday, May 2 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (international) and … read more...
Looking For Action? S&P 1500 Most Volatile Stocks
via: SeekingAlpha at 2018-03-29 04:21:00:000
For traders with a short-term time horizon looking for big moves, we have updated our list of the S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread between the intraday high and low over the last 50 days). The stocks are g… read more...
Looking For Action? S&P 1500 Most Volatile Stocks
via: SeekingAlpha at 2018-03-29 04:21:00:000
For traders with a short-term time horizon looking for big moves, we have updated our list of the S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread between the intraday high and low over the last 50 days). The stocks are g… read more...
Acorda Files Marketing Authorization Application for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-03-26 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA. Acorda is seeking marketing approval in the European Union for INBRIJA, an investigational inhaled levodopa treatment… read more...
Acorda Files Marketing Authorization Application for INBRIJA(TM) (levodopa inhalation powder)
via: Business Wire at 2018-03-26 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA. Acorda is seeking marketing approval in the European Union for INBRIJA, an investigational inhaled levodopa treatment… read more...
Acorda Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-16 12:30:46:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Acorda Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-16 12:30:46:000
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-15 14:37:05:000
Acorda Therapeutics, Inc. (ACOR) Q4 2017 Earnings Conference Call February 15, 2018 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Michael Yee - Jeff… read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Therapeutics misses by $0.44, beats on revenue
via: SeekingAlpha at 2018-02-15 06:01:19:000
Acorda Therapeutics (NASDAQ: ACOR ): Q4 EPS of $0.61 misses by $0.44 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
via: Business Wire at 2018-02-15 06:00:00:000
INBRIJA (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equivalents of $307 million Prosecution of AMPYRA appeal continues Acorda Therapeu… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-14 17:30:06:000
AAN , ACOR , ALE , ARES , AVP , BAM , BBW , BCOR , CBB , CCE , COMM , COWN , CVE , CYBR , ECA , EQM , EQT , FTS , GEL , GPN , HII , HL , HPP , ICLR , INCY , IRWD , KIM , MFA , MTRN , NICE , OMC , PATK , PBF , PBFX , PDS , POOL , RMP , RS , SHOP , SON … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
via: Business Wire at 2018-02-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under Investor Events… read more...
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
via: Business Wire at 2018-02-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under Investor Events… read more...
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
via: Business Wire at 2018-02-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under Investor Events… read more...
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
via: Business Wire at 2018-02-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under Investor Events… read more...
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
via: Business Wire at 2018-02-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under Investor Events… read more...
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
via: Business Wire at 2018-02-08 07:00:00:000
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under Investor Events… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-07 07:54:07:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-07 07:54:07:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-07 07:54:07:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-07 07:54:07:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-07 07:54:07:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-07 07:54:07:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Stocks To Watch: Welcome To The Party Rising Rates
via: SeekingAlpha at 2018-02-03 08:45:32:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c… read more...
Stocks To Watch: Welcome To The Party Rising Rates
via: SeekingAlpha at 2018-02-03 08:45:32:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c… read more...
Stocks To Watch: Welcome To The Party Rising Rates
via: SeekingAlpha at 2018-02-03 08:45:32:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c… read more...
Stocks To Watch: Welcome To The Party Rising Rates
via: SeekingAlpha at 2018-02-03 08:45:32:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c… read more...
Acorda Fourth Quarter/Year End 2017 Update
via: Business Wire at 2018-02-02 07:00:00:000
Webcast/Conference Call Scheduled for February 15, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates onThursday, February 15 at 8:30 a.m. ET. To participate in the … read more...
Acorda Fourth Quarter/Year End 2017 Update
via: Business Wire at 2018-02-02 07:00:00:000
Webcast/Conference Call Scheduled for February 15, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates onThursday, February 15 at 8:30 a.m. ET. To participate in the … read more...
Acorda Fourth Quarter/Year End 2017 Update
via: Business Wire at 2018-02-02 07:00:00:000
Webcast/Conference Call Scheduled for February 15, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates onThursday, February 15 at 8:30 a.m. ET. To participate in the … read more...
Acorda Fourth Quarter/Year End 2017 Update
via: Business Wire at 2018-02-02 07:00:00:000
Webcast/Conference Call Scheduled for February 15, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates onThursday, February 15 at 8:30 a.m. ET. To participate in the … read more...
Acorda Fourth Quarter/Year End 2017 Update
via: Business Wire at 2018-02-02 07:00:00:000
Webcast/Conference Call Scheduled for February 15, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates onThursday, February 15 at 8:30 a.m. ET. To participate in the … read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Biotech Forum Daily Digest For January 26th
via: SeekingAlpha at 2018-01-26 10:21:50:000
Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...
Acorda Therapeutics Is An Attractive Target
via: SeekingAlpha at 2018-01-23 11:17:49:000
Last Friday, Acorda Therapeutics ( ACOR ) surged nearly 9% amid reports that the company was seeing takeover interest from the likes of Biogen ( BIIB ), UCB (UCBJB) and a few other Asian drugmakers. After a year of ups and downs, ACOR has begun 2018 on a very strong note. The stock is alre… read more...
Acorda Therapeutics Is An Attractive Target
via: SeekingAlpha at 2018-01-23 11:17:49:000
Last Friday, Acorda Therapeutics ( ACOR ) surged nearly 9% amid reports that the company was seeing takeover interest from the likes of Biogen ( BIIB ), UCB (UCBJB) and a few other Asian drugmakers. After a year of ups and downs, ACOR has begun 2018 on a very strong note. The stock is alre… read more...
Acorda Therapeutics Is An Attractive Target
via: SeekingAlpha at 2018-01-23 11:17:49:000
Last Friday, Acorda Therapeutics ( ACOR ) surged nearly 9% amid reports that the company was seeing takeover interest from the likes of Biogen ( BIIB ), UCB (UCBJB) and a few other Asian drugmakers. After a year of ups and downs, ACOR has begun 2018 on a very strong note. The stock is alre… read more...
Acorda Therapeutics Is An Attractive Target
via: SeekingAlpha at 2018-01-23 11:17:49:000
Last Friday, Acorda Therapeutics ( ACOR ) surged nearly 9% amid reports that the company was seeing takeover interest from the likes of Biogen ( BIIB ), UCB (UCBJB) and a few other Asian drugmakers. After a year of ups and downs, ACOR has begun 2018 on a very strong note. The stock is alre… read more...
Acorda Therapeutics Is An Attractive Target
via: SeekingAlpha at 2018-01-23 11:17:49:000
Last Friday, Acorda Therapeutics ( ACOR ) surged nearly 9% amid reports that the company was seeing takeover interest from the likes of Biogen ( BIIB ), UCB (UCBJB) and a few other Asian drugmakers. After a year of ups and downs, ACOR has begun 2018 on a very strong note. The stock is alre… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018
via: SeekingAlpha at 2018-01-23 03:52:17:000
Market and sector outlook: S&P 500 index was up 0.81% and could reach above 2950 before we see a meaningful pullback. It is the longest stretch now without a 5% pullback in history, so some caution is warranted. Biotech indexes surged today fueled by news of M&A and exceeded Oct… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018
via: SeekingAlpha at 2018-01-23 03:52:17:000
Market and sector outlook: S&P 500 index was up 0.81% and could reach above 2950 before we see a meaningful pullback. It is the longest stretch now without a 5% pullback in history, so some caution is warranted. Biotech indexes surged today fueled by news of M&A and exceeded Oct… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018
via: SeekingAlpha at 2018-01-23 03:52:17:000
Market and sector outlook: S&P 500 index was up 0.81% and could reach above 2950 before we see a meaningful pullback. It is the longest stretch now without a 5% pullback in history, so some caution is warranted. Biotech indexes surged today fueled by news of M&A and exceeded Oct… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018
via: SeekingAlpha at 2018-01-23 03:52:17:000
Market and sector outlook: S&P 500 index was up 0.81% and could reach above 2950 before we see a meaningful pullback. It is the longest stretch now without a 5% pullback in history, so some caution is warranted. Biotech indexes surged today fueled by news of M&A and exceeded Oct… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018
via: SeekingAlpha at 2018-01-23 03:52:17:000
Market and sector outlook: S&P 500 index was up 0.81% and could reach above 2950 before we see a meaningful pullback. It is the longest stretch now without a 5% pullback in history, so some caution is warranted. Biotech indexes surged today fueled by news of M&A and exceeded Oct… read more...
Biotech Forum Daily Digest For January 21st
via: SeekingAlpha at 2018-01-22 09:45:00:000
An optimist is a man who plant two acorns and buys a hammock . Jean de Lattre de Tassigny Biotech was relatively flat to slightly down last week even as the major indices continued to advance and hit new all-time highs. Money flow is going into those sectors of the econom… read more...
Biotech Forum Daily Digest For January 21st
via: SeekingAlpha at 2018-01-22 09:45:00:000
An optimist is a man who plant two acorns and buys a hammock . Jean de Lattre de Tassigny Biotech was relatively flat to slightly down last week even as the major indices continued to advance and hit new all-time highs. Money flow is going into those sectors of the econom… read more...
Biotech Forum Daily Digest For January 21st
via: SeekingAlpha at 2018-01-22 09:45:00:000
An optimist is a man who plant two acorns and buys a hammock . Jean de Lattre de Tassigny Biotech was relatively flat to slightly down last week even as the major indices continued to advance and hit new all-time highs. Money flow is going into those sectors of the econom… read more...
Biotech Forum Daily Digest For January 21st
via: SeekingAlpha at 2018-01-22 09:45:00:000
An optimist is a man who plant two acorns and buys a hammock . Jean de Lattre de Tassigny Biotech was relatively flat to slightly down last week even as the major indices continued to advance and hit new all-time highs. Money flow is going into those sectors of the econom… read more...
Biotech Forum Daily Digest For January 21st
via: SeekingAlpha at 2018-01-22 09:45:00:000
An optimist is a man who plant two acorns and buys a hammock . Jean de Lattre de Tassigny Biotech was relatively flat to slightly down last week even as the major indices continued to advance and hit new all-time highs. Money flow is going into those sectors of the econom… read more...
Stocks To Watch: Earnings Season Hits Higher Gear
via: SeekingAlpha at 2018-01-20 08:27:52:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...
Stocks To Watch: Earnings Season Hits Higher Gear
via: SeekingAlpha at 2018-01-20 08:27:52:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...
Stocks To Watch: Earnings Season Hits Higher Gear
via: SeekingAlpha at 2018-01-20 08:27:52:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...
Stocks To Watch: Earnings Season Hits Higher Gear
via: SeekingAlpha at 2018-01-20 08:27:52:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...
Stocks To Watch: Earnings Season Hits Higher Gear
via: SeekingAlpha at 2018-01-20 08:27:52:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
via: SeekingAlpha at 2018-01-20 07:59:00:000
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions… read more...
Premarket Gainers as of 9:05 am (1/19/2018)
via: SeekingAlpha at 2018-01-19 09:16:03:000
FORD +63% on acquisition ofintelligent product solutions. More news on: Forward Industries, Inc., Acorda Therapeutics, Inc., Corbus Pharmaceuticals Holdings, Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (1/19/2018)
via: SeekingAlpha at 2018-01-19 09:16:03:000
FORD +63% on acquisition ofintelligent product solutions. More news on: Forward Industries, Inc., Acorda Therapeutics, Inc., Corbus Pharmaceuticals Holdings, Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (1/19/2018)
via: SeekingAlpha at 2018-01-19 09:16:03:000
FORD +63% on acquisition ofintelligent product solutions. More news on: Forward Industries, Inc., Acorda Therapeutics, Inc., Corbus Pharmaceuticals Holdings, Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (1/19/2018)
via: SeekingAlpha at 2018-01-19 09:16:03:000
FORD +63% on acquisition ofintelligent product solutions. More news on: Forward Industries, Inc., Acorda Therapeutics, Inc., Corbus Pharmaceuticals Holdings, Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (1/19/2018)
via: SeekingAlpha at 2018-01-19 09:16:03:000
FORD +63% on acquisition ofintelligent product solutions. More news on: Forward Industries, Inc., Acorda Therapeutics, Inc., Corbus Pharmaceuticals Holdings, Inc., Stocks on the move, Read more … read more...
Stocks making the biggest moves premarket: IBM, AXP, ACOR, LOW, FL, NKE & more
via: CNBC at 2018-01-19 07:39:00:000
No summary available. read more...
Stocks making the biggest moves premarket: IBM, AXP, ACOR, LOW, FL, NKE & more
via: CNBC at 2018-01-19 07:39:00:000
No summary available. read more...
Stocks making the biggest moves premarket: IBM, AXP, ACOR, LOW, FL, NKE & more
via: CNBC at 2018-01-19 07:39:00:000
No summary available. read more...
Stocks making the biggest moves premarket: IBM, AXP, ACOR, LOW, FL, NKE & more
via: CNBC at 2018-01-19 07:39:00:000
No summary available. read more...
Stocks making the biggest moves premarket: IBM, AXP, ACOR, LOW, FL, NKE & more
via: CNBC at 2018-01-19 07:39:00:000
No summary available. read more...
Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
via: SeekingAlpha at 2018-01-19 07:30:57:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 9% premarket on light volume on the heels of reports that Biogen (NASDAQ: BIIB ), UCB S.A. ( OTCPK:UCBJF ) and possibly certain Asian drugmakers are mulling bids. More news on: Acorda Therapeutics, Inc., Biogen Inc., UCB S.A., Healthc… read more...
Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
via: SeekingAlpha at 2018-01-19 07:30:57:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 9% premarket on light volume on the heels of reports that Biogen (NASDAQ: BIIB ), UCB S.A. ( OTCPK:UCBJF ) and possibly certain Asian drugmakers are mulling bids. More news on: Acorda Therapeutics, Inc., Biogen Inc., UCB S.A., Healthc… read more...
Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
via: SeekingAlpha at 2018-01-19 07:30:57:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 9% premarket on light volume on the heels of reports that Biogen (NASDAQ: BIIB ), UCB S.A. ( OTCPK:UCBJF ) and possibly certain Asian drugmakers are mulling bids. More news on: Acorda Therapeutics, Inc., Biogen Inc., UCB S.A., Healthc… read more...
Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
via: SeekingAlpha at 2018-01-19 07:30:57:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 9% premarket on light volume on the heels of reports that Biogen (NASDAQ: BIIB ), UCB S.A. ( OTCPK:UCBJF ) and possibly certain Asian drugmakers are mulling bids. More news on: Acorda Therapeutics, Inc., Biogen Inc., UCB S.A., Healthc… read more...
Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
via: SeekingAlpha at 2018-01-19 07:30:57:000
Acorda Therapeutics (NASDAQ: ACOR ) is up 9% premarket on light volume on the heels of reports that Biogen (NASDAQ: BIIB ), UCB S.A. ( OTCPK:UCBJF ) and possibly certain Asian drugmakers are mulling bids. More news on: Acorda Therapeutics, Inc., Biogen Inc., UCB S.A., Healthc… read more...
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Acorda Therapeutics, Inc.
via: Business Wire at 2018-01-12 08:00:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc. (NASDAQ: ACOR) (Acorda or the Company) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Companys securities between April 1… read more...
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Acorda Therapeutics, Inc.
via: Business Wire at 2018-01-12 08:00:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc. (NASDAQ: ACOR) (Acorda or the Company) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Companys securities between April 1… read more...
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Acorda Therapeutics, Inc.
via: Business Wire at 2018-01-12 08:00:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc. (NASDAQ: ACOR) (Acorda or the Company) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Companys securities between April 1… read more...
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Acorda Therapeutics, Inc.
via: Business Wire at 2018-01-12 08:00:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc. (NASDAQ: ACOR) (Acorda or the Company) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Companys securities between April 1… read more...
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Acorda Therapeutics, Inc.
via: Business Wire at 2018-01-12 08:00:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc. (NASDAQ: ACOR) (Acorda or the Company) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Companys securities between April 1… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|